|Day Low/High||137.67 / 140.15|
|52 Wk Low/High||118.62 / 148.99|
Here we go folks -- another day, another diary. Today I, Chris Versace, once again am sitting in for Doug. It's going to be an action-packed day, with a smattering of earnings from Bank of America , Goldman Sachs , Johnson & Johnson and more than a ...
As always, it was good seeing everyone on the Daily Diary sitting in for Doug Kass. Lots of good conversation despite a quiet day in the market with the market indices ending the day pretty much where they started. Very narrow range of trading throu...
Procter & Gamble proxy fight is an intriguing distraction.
While the Dow is trading sideways, Nasdaq downtrend may already have started.
The market is telling us that the easy money in large-cap names has already been made.
The days of rapid growth are far behind Japan. So can these Tokyo listings deliver as much bite as the FANGs?
China's tech giants Alibaba and Tencent now rank among the 10 largest companies in the world. How long before they're 1 and 2?
A rotation that started as the minor chord of the rotational symphony and is now the major one.
There's a herd mentality around FANG stocks, but herds tend to change direction quickly.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
This market has diverged from some of its usual patterns.
Looking for growth overseas? You're not seeing triple, you're seeing 3M.
From price momentum to signs of irrational exuberance, several things have me worried.
Stocks, bonds, gold and bitcoin are rising, but that isn't cause for alarm.
The handwringers will be out in full force. Their fear creates buying opportunities.
Uber's first quarter loss was less than the $991 million loss reported 3 months ago.
The market held up from the start to the flag today (or at least until I wrote this at about 3PM. At the hour some slippage seen with sixty minutes of trading to go. The close will, as always, be governed by The Last Program Standing. First bottom...
Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.
Let's pull the band aid off the charts, carefully.
Biotech investors should keep a close eye on the progress in this huge potential market.
It is a very muddled market, and that demands that we stay patient and wait for greater clarity to develop.